Buyside Biotech Landscape

The biotech buyside landscape is indeed diverse, with distinct verticals that cater to different stages of company development and investment strategies. Here's a breakdown based on the most helpful WSO content:

1. Hedge Funds

• Single Manager (SM) vs. Multi-Manager (MM): While the distinction isn't explicitly detailed in the context, hedge funds in biotech often focus on public equities, with some specializing in late-stage private investments. SM funds are typically run by a single portfolio manager, while MM funds have multiple PMs managing separate books.
• Focus: Public biotech companies, sometimes participating in late-stage private rounds.
• Key Players: Not explicitly listed, but crossover funds often overlap with hedge funds in this space.

2. Crossover Funds

• Definition: These funds invest in the last private round of a biotech company and then anchor the IPO. They bridge the gap between private and public markets.
• Focus: Late-stage private companies with a clear path to IPO.
• Key Players: Hedge funds and mutual funds often act as crossover investors.

3. Incubation Platforms

• Definition: These platforms create and fund biotech startups from the ground up, often providing operational support and scientific expertise.
• Focus: Early-stage biotech companies, often "science projects."
• Key Players: Not explicitly mentioned, but firms like Flagship Pioneering are known for this model.

4. Traditional Venture Capital (VC)

• Definition: VCs provide funding to startups or young businesses with long-term growth potential.
• Focus: Early-stage companies, often in healthcare and tech.
• Key Players: Generalist VCs that occasionally venture into biotech.

5. Biotech-Specific VCs

• Definition: These are specialized VCs focused solely on biotech and life sciences.
• Focus: Early-stage biotech companies, often leading Series A deals.
• Key Players: Atlas Venture, Third Rock, 5AM Ventures, Flagship, Orbimed, Versant, ARCH. These are considered the "MBB/bulge bracket" of biotech VC.

6. Drug Royalty Financing

• Definition: These platforms invest in royalty streams from approved drugs, providing non-dilutive capital to biotech companies.
• Focus: Revenue-generating biotech companies or those with approved drugs.

7. PE-Esque Platforms

• Definition: Private equity-style platforms that invest in biotech companies, often bridging the gap between VC and public markets.
• Focus: Late-stage companies or those with commercialized products.
• Key Players: BXLS (Blackstone Life Sciences), Bain Capital's life sciences fund.

Key Differences Between Crossover, VC, and PE:

• Crossover Funds: Focus on late-stage private rounds and IPO anchoring, blending private and public market strategies.
• VCs: Primarily early-stage investments, with biotech-specific VCs often requiring deep scientific expertise (e.g., PhDs).
• PE: More transaction-oriented, focusing on stable businesses with healthy growth prospects, often in later stages.

This breakdown highlights the diversity and specialization within the biotech buyside landscape, with each vertical catering to different stages of company development and requiring unique expertise.

Sources: Healthcare / Biotech Venture Capital?, Biotech finance: from IB to VC / HF to funded startup, Divergence in the Drug Businesses: Pharmaceuticals and Biotechnology, Private Equity vs. Venture Capital in 2018, IB vs PE vs VC : The rundown